Discovery of Sexual Dimorphisms in Metabolic and Genetic Biomarkers by Mittelstrass, Kirstin et al.
Discovery of Sexual Dimorphisms in Metabolic and
Genetic Biomarkers
Kirstin Mittelstrass1., Janina S. Ried2., Zhonghao Yu1., Jan Krumsiek3, Christian Gieger2, Cornelia
Prehn4, Werner Roemisch-Margl3, Alexey Polonikov5, Annette Peters6, Fabian J. Theis3, Thomas
Meitinger7,8, Florian Kronenberg9, Stephan Weidinger10, Heinz Erich Wichmann11,12,13, Karsten
Suhre3,14,15, Rui Wang-Sattler1, Jerzy Adamski4,16"*, Thomas Illig1"*
1Unit of Molecular Epidemiology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany, 2 Institute of Genetic
Epidemiology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany, 3 Institute of Bioinformatics and Systems Biology,
Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany, 4 Institute of Experimental Genetics, Genome Analysis Center,
Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany, 5Department of Biology, Medical Genetics, and Ecology, Kursk State
Medical University, Kursk, Russia, 6 Institute of Epidemiology II, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany,
7 Institute of Human Genetics, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany, 8 Institute of Human Genetics,
Klinikum Rechts der Isar, Technische Universita¨t Mu¨nchen, Munich, Germany, 9Division of Genetic Epidemiology, Department of Medical Genetics and Molecular and
Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria, 10Department of Dermatology, Venereology, and Allergy, University Hospital Schleswig-Holstein,
Kiel, Germay, 11 Institute of Epidemiology I, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany, 12 Institute of Medical
Informatics, Biometry, and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universita¨t, Munich, Germany, 13 Klinikum Grosshadern, Munich, Germany,
14 Faculty of Biology, Ludwig-Maximilians-Universita¨t, Planegg-Martinsried, Germany, 15Weill Cornell Medical College in Qatar, Qatar Foundation, Education City, Doha,
Qatar, 16 Lehrstuhl fu¨r Experimentelle Genetik, Technische Universita¨t Mu¨nchen, Munich, Germany
Abstract
Metabolomic profiling and the integration of whole-genome genetic association data has proven to be a powerful tool to
comprehensively explore gene regulatory networks and to investigate the effects of genetic variation at the molecular level.
Serum metabolite concentrations allow a direct readout of biological processes, and association of specific metabolomic
signatures with complex diseases such as Alzheimer’s disease and cardiovascular and metabolic disorders has been shown.
There are well-known correlations between sex and the incidence, prevalence, age of onset, symptoms, and severity of a
disease, as well as the reaction to drugs. However, most of the studies published so far did not consider the role of sexual
dimorphism and did not analyse their data stratified by gender. This study investigated sex-specific differences of serum
metabolite concentrations and their underlying genetic determination. For discovery and replication we used more than
3,300 independent individuals from KORA F3 and F4 with metabolite measurements of 131 metabolites, including amino
acids, phosphatidylcholines, sphingomyelins, acylcarnitines, and C6-sugars. A linear regression approach revealed significant
concentration differences between males and females for 102 out of 131 metabolites (p-values,3.861024; Bonferroni-
corrected threshold). Sex-specific genome-wide association studies (GWAS) showed genome-wide significant differences in
beta-estimates for SNPs in the CPS1 locus (carbamoyl-phosphate synthase 1, significance level: p,3.8610210; Bonferroni-
corrected threshold) for glycine. We showed that the metabolite profiles of males and females are significantly different and,
furthermore, that specific genetic variants in metabolism-related genes depict sexual dimorphism. Our study provides new
important insights into sex-specific differences of cell regulatory processes and underscores that studies should consider
sex-specific effects in design and interpretation.
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Introduction
Metabolomics provides a powerful tool to analyse physiological
and disease-induced biological states on the molecular level, taking
into account both the organism’s intrinsic properties, i.e. genetic
factors, and the effects of lifestyle, diet, and environment. The
development of sophisticated analytic platforms and modern
computational tools to handle increasingly complex data now
enables the quantification of hundreds of metabolites from
complex biological samples with a high throughput rate. These
advancements support the integration of metabolomic profiles
with genetic, epigenetic, transcriptomic and proteomic data for
holistic systems biology approaches. Recently, common genetic
variants have been demonstrated to exert large effects on
individual metabolic capacities called ‘‘genetically determined
metabotypes’’ [1,2]. Therefore genetic variants in metabolism-
related genes led to specific and clearly differentiated metabolic
phenotypes [1,3]. Knowledge on such genetically determined
metabotypes is of crucial importance to understand the contribu-
tion and complex interaction of genes, proteins and metabolites in
health and disease. Consequently, genetic studies can help to
elucidate the direction of effects between metabolites and a specific
disease. Thus, the combination of genetic and metabolic markers
is an important emerging approach for biological research. To
uncover potentially confounding influences on the interpretation
of metabolic results, it is important to minimize the occurring
confounders on human serum metabolites in a population-based
study that has not been subjected to lifestyle and dietary controls.
Pointed out recently, gender inequalities are another increasingly
recognized problem in both basic research and clinical medicine
[4]. Nevertheless, many published studies did not analyse their
data stratified by sex [4–6] although there is a strong correlation
between sex and the incidence, prevalence, age at onset, symptoms
and severity of a disease, as well as the reaction to drugs [7,8]. A
survey of studies published in 2004 of nine different medical
journals found that only 37% of participants were women (24%
when restricted to drug trials), and only 13% of studies analysed
data by sex [4]. Therefore we systematically assessed the effect of
sex on serum metabolites in a large population-based cohort [9].
Furthermore, we investigated whether there are sex-specific
differences in the genetic determination of metabotypes.
Results
Phenotypic Metabotype Differences between Males and
Females
All phenotypic analysis steps were performed on population-
based cohort data from KORA F4 (1452 males, 1552 females) and
KORA F3 (197 males, 180 females, Figure S1) with fasting serum
concentrations of 131 metabolites. The metabolites covered a
biologically relevant panel that could be divided into five
subgroups such as amino acids, sugars, acylcarnitines and
phospholipids. Further information concerning the study popula-
tion, sampling methods and the metabolite panel are described in
the Material and Methods section and in the Tables S1, S6, and
S7 and Figure S3.
A Partial Least Square (PLS) analysis [10] of all metabolites
showed that there were major differences of mean serum
metabolite concentrations between males and females, as the
values for the first two PLS components clustered clearly for men
and women (Figure 1).
Motivated by the global gender differences in metabolite
concentrations shown by PLS analysis, furthermore, the effect of
sex on each metabolite was analysed using linear regression
analysis. For each metabolite we calculated a linear regression with
the logarithm of the metabolite concentration as dependent and
sex as explanatory variable besides the covariates age, BMI and
internal batch. The test whether the explanatory variable sex has a
significant effect on the logarithm of the metabolite concentration
revealed significant effects of gender in 102 of 131 metabolites (p-
value below the Bonferroni-corrected significance level of 3.86
1024). At least one metabolite of each subgroup including amino
acids, acylcarnitines, phosphatidylcholines, lysophosphatidylcho-
lines and sphingomyelins showed significant sex-specific differenc-
es in metabolite concentrations. In Table 1 the results of the linear
regression analysis for representatives of each subgroup are
presented, the complete list of results can be found in the Table
S2.
The linear regression analysis showed that the concentrations of
most amino acids were significantly higher in males except for the
concentrations of glycine (effect of sex: ß=20.13, p-value=2.3
610246) and serine (effect of sex: ß=20.13, p-value=1.0610212)
which displayed higher concentrations in females. (Table 1, Table
S2). The relative sex-specific difference for glycine was D=214%
(Table S8). That means that the mean concentration in men was
14% lower than in women (see Material and Methods). The levels of
most serum acylcarnitines were significantly higher in males
compared to females (Table 1, Table S2 and S8). The concentrations
of phosphatidylcholines (PC ae Cx:y or PC aa Cx:y) tended to be
significantly lower in males compared to females. The most
significant difference between gender could be seen for the
phosphatidylcholine PC aa C32:3 (D=217.9%, p-value=4.4
6102108), whereas lysophosphatidylcholine (lysoPC a Cx:y) concen-
trations were higher in males compared to females. In contrast, the
concentrations of most sphingomyelins were significantly lower in
men than in women (Table 1, Table S2 and S8). The concentration
of H1 which is the sum of C6-sugars, was significantly higher in
males compared to females (D=7.3%, p-value=6.2610227) (Table 1,
Table S2 and S8). Figure 2 systematically reviews the sex-specific
metabolite variations identified in this study.
The adjustment for different covariates (e.g.: waist-hip ratio
(WHR), HDL (high density lipoprotein), LDL (low density
Author Summary
The combination of genomic and metabolic studies
during the last years has provided astonishing results.
However, most of the studies published so far did not
consider the role of sexual dimorphism and did not
analyse their data stratified by sex. The investigation of 131
serum metabolite concentrations of .3,300 population-
based samples (KORA F3/F4) revealed significant differ-
ences in the metabolite profile of males and females.
Furthermore, a genome-wide picture of sex-specific
genetic variations in human metabolism (.2,000 subjects
from KORA F3/F4 cohorts) was investigated. Sex-specific
genome-wide association studies (GWAS) showed differ-
ences in the effect of genetic variations on metabolites in
men and women. SNPs in the CPS1 (carbamoyl-phosphate
synthase 1) locus showed genome-wide significant differ-
ences in beta-estimates of sex-specific association analysis
(significance level: 3.8610210) for glycine. As global
metabolomic techniques are more and more refined to
identify more compounds in single biological samples, the
predictive power of this new technology will greatly
increase. This suggests that metabolites, which may be
used as predictive biomarkers to indicate the presence or
severity of a disease, have to be used selectively
depending on sex.
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lipoprotein), triglycerides, type 2 diabetes, smoking and high
alcohol consumption) did not affect the sex-specific differences in
the metabolite concentrations extensively. The majority of the
high significant sex-effects remained significant. In particular,
adjustments for lipid parameter (HDL, LDL and triglycerides),
type 2 diabetes, smoking and high alcohol consumption did not
influence our main findings. If WHR was included into the linear
regression model as covariate replacing BMI or as additional
covariate besides BMI, the p-values of the sex-effect on metabolites
changed, but for most metabolite concentrations the gender-
differences remained significant. Interestingly, there were seven
PC aa Cx:ys and Lyso PC a C17:0 that showed significant
differences between sexes while adjusting for age and WHR but
not for BMI and age adjustment. We refer the interested reader to
Table S2.
As replication the same linear regression approach (covariates:
age, BMI) was applied to the KORA F3 cohort which included
377 individuals (Figure S1). Despite this smaller sample size for 63
of 102 metabolites with a significant effect of sex in KORA F4, the
effect of sex in KORA F3 had the same direction and a significant
p-value lower than the Bonferroni-corrected replication significance
level corrected for the 102 metabolites taken forward to replication
(0.05/102= 4.961024). That means 61.8% of the sex-specific
differences could be replicated (Table 1, Table S3).
A combined meta-analysis of KORA F4 and KORA F3
revealed 113 metabolites with a significant effect of sex
(Bonferroni-corrected meta-analysis significance level: p,3.86
1024) (Table S3).
Sex-Specific Effects in the Metabolic Network
We further investigated how groups of metabolites share
pairwise correlations, that mean similar effects, and how the sex-
specific effects propagate through the metabolic network.
Therefore we calculated a partial correlation matrix between all
metabolites, corrected against age, sex and BMI [11]. The
resulting network, which is also referred to as a Gaussian graphical
model (see Material and Methods), was annotated with the results
from the linear regression analysis to get a comprehensive picture
of sex-effects in this data-driven metabolic network (Figure 3). We
applied a cut-off of r = 0.3 (r = partial correlation coefficient) in
order to emphasize strong inter-metabolite effects. We observe a
general structuring of the network into members from similar
metabolic classes, e.g. the amino acids, the phosphatidylcholines,
sphingomyelins and acylcarnitines (Figure 3). Direct correlations
between metabolites, as represented by partial correlation
coefficients, are rare in this metabolite panel with only around
1% of all partial correlations showing a strong effect above r = 0.3
(Figure S4 and S5). For this specific cut-off we obtained 14 non-
singleton groups, which can be regarded as independently
regulated phenotypes within the measured metabolite panel.
Detailed description of the distribution of partial correlations and
the group structure in the network can be found in Figure S4 and
S5. The low connectedness of the network is in line with findings
from Krumsiek et al. 2011 [11] who demonstrated that Gaussian
graphical models are sparsely connected on the one hand, but
specifically exclude indirect metabolic interactions on the other
hand.
Strikingly, sex-specific effects appear to be localized with respect
to metabolic classes and connections in the partial correlation
matrix. For instance, while most sphingomyelin concentrations
have been shown to be higher in females, we also observe them to
be a connected component in the GGM. Similarly, acylcarnitines
are higher in males and also share partial correlation edges, mostly
with other acylcarnitines (Figure 3). Interestingly, we observed
three metabolite pairs from the PC aa and lyso-PC classes,
respectively, which constitute a side chain length difference of 18
carbon atoms (yellow shaded metabolite pairs, Figure 3).
Genotypic Metabotype Differences between Males and
Females
For the identification of differences in genetically determined
metabotypes, we used a subpopulation of 1809 participants of the
Figure 1. Two dimensional partial least square (PLS) analyses showing the contribution of 131 metabolites in males and females.
doi:10.1371/journal.pgen.1002215.g001
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KORA F4 (Geno-KORA F4) study. The replication was done in
an independent subsample of KORA F4 (Rep-KORA F4) and in a
subsample of the KORA F3 (Rep-KORA F3) cohort, see Material
and Methods for details and Figure S1.
Sex-stratified genome-wide association analysis adjusted for age
and BMI were performed for logarithmized concentrations of all
metabolites. In order to reveal gender differences we tested the
estimated SNP effects for heterogeneity between men and women
(see Material and Methods, Figure 4 and Figure S2). We applied a
Bonferroni-corrected genome-wide significance level of 561028/
131= 3.8610210. All SNPs with a minor allele frequency (maf)
lower than 1% in men or in women were excluded. Moreover,
SNPs with a low quality of imputation (rsq,0.4) were also
excluded. Eight SNPs on chromosome 2 showed genome-wide
significant differences in SNP effects (beta-estimates) between men
and women for association with glycine (Table 2). The absolute
beta-estimates of all eight significant SNPs were higher in women
compared to men. The strongest gender difference was seen at
SNP rs715 with a genome-wide significant p-value of 3.65610210
for the test of beta-estimate differences. For men the observed
effect of rs715 was -0.067 and for women 20.2 (Table 2). SNP
rs715 is part of the 39 UTR region of the CPS1 gene. SNP
rs7422339 with a p-value of 3.24610211 for the test of beta-
estimate differences is in a non synonymous coding region of
CPS1. All other significant SNPs are intergenetic but located in the
same region (Table S5). Local association plots for the association
of this region with glycine for males and females are presented in
Figure S3. The differences in beta-estimates remained significant
for GWAs with adjustment for WHR instead of BMI or BMI and
WHR combined (Table S4).
The significant differences in beta-estimates between men and
women for the association of the eight reported SNPs with glycine
were replicated in two independent cohorts Rep-KORA F4 and
Rep-KORA F3, including 788 women and 758 men. In the first
replication cohort Rep-KORA F4 (583 men, 635 women) the
absolute beta-estimate for SNP rs7422339 was also higher in
women (beta =20.225) compared to men (beta =20.081). The
absolute difference of the beta-estimates for SNP rs7422339 was
with 0.144 similar to the difference observed in the discovery
sample. The p-value of the test for difference in beta-estimates of
the replication was 1.3610213. The other seven SNPs were not
available for the Rep-KORA F4 cohort due to other genotyping
Table 1. Phenotypic metabotype differences between males and females of the discovery set (KORA F4) and the replication study
(KORA F3).
Discovery Replication Metaanalysis
metabolites ß p-value r2 ß p-value r2 ß p-value
acylcarnitines
C18 0.146 5.6E-57 21.1% 0.092 3.6E-04 8.4% 0.140 2.5E-61
C10 0.089 2.3E-10 7.9% 0.068 1.0E-01 7.4% 0.087 5.8E-11
C10.1 0.088 5.2E-14 15.9% 0.061 1.0E-01 10.2% 0.085 1.3E-14
amino acids
xLeu 0.206 1.6E-190 30.2% 0.165 1.1E-15 22.9% 0.202 3.8E-235
Val 0.142 1.9E-78 23.9% 0.096 2.4E-07 18.6% 0.136 5.4E-88
Gly 20.130 9.1E-46 10.9% 20.112 2.4E-06 11.1% 20.128 3.4E-52
phosphatidylcholines
PC aa C32:3 20.192 1.4E-106 15.6% 20.272 1.4E-23 24.5% 20.200 1.3E-138
PC aa C28:1 20.133 1.1E-53 8.5% 20.219 4.7E-18 18.8% 20.143 1.8E-71
PC ae C40:3 20.160 5.0E-99 18.7% 20.177 2.6E-14 16.0% 20.161 3.0E-120
PC ae C30:2 20.152 9.1E-53 8.1% 20.214 1.1E-22 22.8% 20.164 4.2E-77
lysophosphatidylcholines
lysoPC a C20:4 0.191 5.4E-62 10.8% 0.125 9.7E-05 8.6% 0.184 2.1E-67
lysoPC a C18:2 0.183 6.2E-55 22.6% 0.136 4.7E-05 17.6% 0.178 1.8E-60
lysoPC a C18:1 0.145 1.4E-41 12.7% 0.106 1.9E-04 16.3% 0.140 1.5E-45
sphingomyelins
SM (OH) C22:2 20.228 1.1E-124 19.6% 20.274 3.5E-25 27.3% 20.234 1.7E-163
SM C18:1 20.200 1.3E-101 20.1% 20.266 3.4E-26 27.0% 20.209 1.1E-136
SM C20:2 20.283 7.5E-100 17.7% 20.280 6.8E-26 25.8% 20.282 1.0E-135
hexoses
H1 0.065 6.2E-27 10.5% 0.029 1.6E-01 7.4% 0.062 3.0E-27
P-values were calculated by a linear regression model with metabolites as dependent variable and sex as explanatory variable adjusted for age and BMI. Presented is a
set of results of highly significant metabolite concentration differences between males and females of each metabolite subclass out of the 131 tested metabolites. A full
list of results for all metabolites and additional information on the complete metabolite panel is provided as supplementary data (Table S2 and S3). Significance level
after Bonferroni-correction is p-value = 3.8610-4.
C5 = valerylcarnitine, C0 = carnitine, C18 = octadecanoylcarnitine, xLeu = isoleucine+leucine, Val = valerine, Gly = glycine, PC aa Cx:y = phosphatidylcholine diacyl
x:y, PC ae Cx:y = phosphatidylcholine acyl-akyl Cx:y, LysoPC a Cx:y = lysophosphatidylcholine acyl Cx:y, SM (OH) Cx:y = hydroxyshingomyeline Cx:y, SM Cx:y =
shingomyelin Cx:y; ß = beta-estimate of linear regression, r2 = explained variance.
doi:10.1371/journal.pgen.1002215.t001
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methods. In the second but smaller Rep-KORA F3 cohort seven
of the eight SNPs were available. For SNP rs7422339 we observed
that the absolute beta-estimate in men (beta =20.115) was also
lower than the absolute beta-estimate in women (beta = 20.229).
The absolute difference of the beta-estimates for SNP rs7422339
was 0.144 similar to the absolute difference in beta-estimates
observed in the discovery and the first replication cohort (Rep-
KORA F4). The p-value for the test of difference in beta-estimates
was not significant in Rep-KORA F3 (p-value=0.032). For the
remaining six SNPs, which were taken forward for replication in
Rep-KORA F3 the beta-estimates were also lower in males
compared to females but the p-values of the test of beta-differences
between men and women were not significantly replicated in the
Rep-KORA F3 cohort (Table 2).
Discussion
There have been only few studies addressing metabolic
differences between males and females, and most of these studies
were rather small in sample size and determined only a small
number of metabolites [5,12]. We investigated a large population-
based study with sufficient statistical power to examine associations
within subgroups and a large number of metabolites. Our findings
shed light on sex-specific architecture of the human metabolome
and provide clues on biochemical mechanisms that might explain
observed differences in susceptibility and time course of the
development of common diseases in males and females. Our data
provided new insights into sex-specific metabotype differences.
Combining results from linear regression with partial correlation
analysis (resulting in a Gaussian graphical model) yielded interesting
insights into how sex-specific concentration differences spread over
the metabolic network (Figure 3). The analysis suggests that sex-
specific concentration differences affect whole metabolic pathways
rather than being randomly spread over the different metabolites. In
addition, we found three interesting inter-class associations between
PCaa/PCae species and lyso PC species (highlighted in yellow in
Figure 3). Those pairs shared a strong partial correlation but
displayed differential concentration patterns with respect to gender
effects. Furthermore, these pairs displayed a fatty acid residue
difference of C18:0, indicating that this fatty acid species might be a
key compound giving rise to opposing metabolic gender effects.
Direct experimental evidence indicated a role for sphingolipids
(sphingomyelins and ceramides) in several common complex
chronic disease processes including atherosclerotic plaque forma-
tion, myocardial infarction (MI), cardiomyopathy, pancreatic beta
cell failure, insulin resistance, coronary heart disease and type 2
diabetes (T2D) [13,14]. Already young children (between birth
and 4 years old, with low levels of sex-hormones) may reveal
significant sex-specific differences in plasma sphingolipid concen-
trations [15]. Our observations described new sex-specific
Figure 2. Systematic view of metabotype variations in the metabolism of males and females. It also shows the suggestive locus that is
located in a gene encoding an enzyme that is central in human metabolism. CPS1 is related to the amino acid metabolism. For this locus the
metabolite with the strongest association is provided (green box). A blue arrow indicates metabolite concentrations which are higher in men than in
women; green arrows vice versa.
doi:10.1371/journal.pgen.1002215.g002
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differences, while other lipid-derived molecules, like bile acids,
were already demonstrated not to be sex-specific [16]. Therefore
sphingomyelins represent important intermediate phenotypes. The
concentration differences between males and females of acylcarni-
tines described in this study coincide with previous findings
showing that carnitine (C0) and acetylcarnitine (C2) concentra-
tions were higher in males than in females[17,18]. Phosphatidyl-
cholines, as demonstrated in this study, are another gender-specific
phenotype. Ghrelin (controlling energy homeostasis and pituitary
hormone secretion in humans) levels have been shown to be
similar in men and women and did not vary by menopausal status
or in association with cortisol levels [19]. These findings of our and
other studies urgently suggest when using metabolites for disease
prediction gender has to be strictly taken into account.
A previously published non sex-stratified GWA study on
metabolites based on the same population Geno-KORA F4
reported 15 loci which showed genome-wide significant associa-
tions with at least one metabolite concentration or ratio [1].
Besides others the locus CPS1 was found to have a significant effect
on glycine concentrations. But the findings of this sex-stratified
genome-wide association analysis revealed that the genetic
determination of CPS1 differs significantly between males and
females. Therefore it is important to analyse the data stratified by
sex. SNP rs74223369 on chromosome 2 in the 39 UTR region of
the gene CPS1 showed a genome-wide significant difference in
beta-estimates between men and women for association with
glycine. The gender-specific effect of SNP rs7422339 was
significantly replicated as the difference between the beta-estimates
of men and women was of the same direction in the discovery
sample and in the replication cohort Rep-KORA F4 and the p-
value of the test of differences was lower than the replication
significance niveau (0.05/8). The other SNPs of the CPS1 gene
region also showed significant gender-specific effects but these
effects could not be replicated in the Rep-KORA F3 cohort. As
the effect-sizes and differences for the SNP rs7422339 are similar
and at least for the other SNPs are pointing into the same direction
as in the discovery set, the failed replication in Rep-KORA F3
might be a problem of power due to the smaller sample size.
CPS1, which encodes the mitochondrial enzyme CPS1, plays a
pivotal role in protein and nitrogen metabolism catalyzing the first
committed step of the hepatic urea cycle. Once ammonia has
entered the mitochondria via glutamine or glutamate, CPS1 adds
the ammonia to bicarbonate along with a phosphate group to form
carbamoyl phosphate. Carbamoyl phosphate is then put into the
urea cycle. The hepatic urea cycle is responsible for the elimination
of ammonia in the form of urea as well as the synthesis of arginine.
Among others, Do¨ring et al. 2008 could show that there is strong
evidence that, in addition to environmental components, a strong
genetic and sex-specific control influences the regulation of blood
uric acid concentration. They showed that the proportion of the
Figure 3. Gaussian graphical model of all measured metabolites illustrating the correlation strength and the propagation of
gender-specific effects through the underlying metabolic network. Each node represents one metabolite whereas edge weights correspond
to the strength of partial correlation. Only edges with a partial correlation above r = 0.3 are shown. Node colouring represents the strength of
association (measured using b from linear regression analysis) towards either males or females. Metabolite names marked with a star * represent
significantly different metabolites between genders. Yellow highlighted pairs of metabolites differ by a C18:0 fatty acid residue.
doi:10.1371/journal.pgen.1002215.g003
Sex-Specific Metabotypes in Human Metabolism
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variance of serum uric acid concentrations explained by SLC2A9
genotypes was about 1.2% in men and 6% in women [12].
Brandsta¨tter et al. 2010 also observed a sex-specific interaction with
genetic association of atherogenic uric acid concentrations [20].
Pare´ et al. 2009 described that the CPS1 SNP rs7422339, which
encodes the substitution of asparagine to threonine (T1405N) in the
region critical for N-acetyl-glutamate binding resulting in 20% to
30% higher enzymatic activity [21], is associated with homocysteine
also in a sex-specific manner in their study [22]. Also in an Asian
population the effects of the genetic variations of the CPS1 gene
were stronger in women than in men [23].
Interestingly a meta-analysis of genome-wide association data in
67,093 individuals also of European ancestry identified recently
CPS1 to affect creatinine production and secretion in Chronic
Kidney Disease (CKD) [24]. Hicks et al. 2009 performed a GWAS
of different circulating sphingolipids in five diverse European
populations [3]. They could show associations of genetic loci with
several lipid species but did not analyse their data stratified by sex.
There is just some evidence for loci with differential sex-effects
influencing classical lipids like HDL [25]. Therefore identification
of sex-specific genetic variants, that alter the homeostasis of key
metabolites in males and in females, will lead to a better functional
understanding of the genetics of complex disorders.
As global ‘omics’-techniques are more and more refined to identify
more compounds in single biological samples, the predictive power of
these new technologies will greatly increase. Metabolite concentration
profiles and genomic data can be used as predictive biomarkers to
indicate the presence or severity of a disease depending on gender.
Our study provides new important insights into sex-specific
differences of cell regulatory processes and underscores that studies
should consider gender-specific effects in design and interpretation.
Our findings help to understand biochemical mechanisms underlying
sexual dimorphism, a phenomenon which may explain the
differential susceptibility to common diseases in males and females.
Materials and Methods
Ethics Statement
Written informed consent has been given by each participant.
The study, including the protocols for subject recruitment and
assessment and the informed consent for participants, was
reviewed and approved by the local ethical committee (Bayerische
Landesa¨rztekammer).
Study Population
The KORA S4 survey, an independent population-based sample
from the general population living in the region of Augsburg,
Southern Germany, was conducted in 1999/2001. The standardized
examinations applied in the survey (4261 participants) have been
described in detail elsewhere [1,9,26]. A total of 3080 subjects
participated in a follow-up examination of S4 in 2006-08 (KORA
F4), comprising individuals who, at that time, were aged 32–81 years
(Figure S3). In a sample of 3061 individuals metabolomics data was
available. This subgroup was used as discovery sample of the
phenotypic analysis. For the GWAS the 3061 KORA F4 individuals
with metabolomics measurements were divided into two subgroups.
First, a subgroup of 1809 individuals from KORA F4 with, who were
genotyped using a genome-wide SNP-array (see section genotyping
and imputation): Geno-KORA F4. Second, a subgroup of 1218
individuals from KORA F4 with genotyping data generated by
Metabo-Chip from Illumina: Rep-KORA F4. Since Geno-KORA
F4 and Rep-KORA F4 are non overlapping subgroups of individuals
from the KORA F4 cohort they can be considered independent.
Therefore it was possible to take Geno-KORA F4 as discovery
sample and Rep-KORA F4 as first replication sample for the GWAS.
The KORA F3 cohort is a ten years follow-up survey of the
KORA S3 survey examined in 1994–1995 as described previously
[26,27]. For the replication step of the phenotypic analysis
randomly selected 197 males and 180 females (aged 55–79 years)
from the KORA F3 cohort were taken. For 328 individuals (175
males, 153 females) genome-wide genotypes were available. These
were used as second replication cohort for the GWAS. No
evidence of population stratification was found in multiple
published analyses using the KORA cohort [28]. The KORA
F3 and F4 surveys are completely independent with no overlap of
individuals (Figure S3).
Blood Sampling
Blood samples for metabolic analysis were collected during the
years 2006 and 2008 in parallel with the KORA F4 examinations
Figure 4. Manhattan plots for gender-specific genome-wide beta-differences for the metabolite glycine. Genome-wide significant beta-
differences are plotted in red (significance level p,3.8610210).
doi:10.1371/journal.pgen.1002215.g004
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as described in [1,2], and were deep frozen at 280uC until
metabolomic analysis. To avoid variation due to circadian rhythm,
the blood samples were drawn in the morning between 8:00 and
10:00 am after overnight fasting. Material was immediately
horizontal shaken (10 min), followed by 40 min resting at 4uC to
obtain complete coagulation. The material was then centrifuged
(2000 g; 4uC). Serum was aliquoted and kept for 2–4 hours at
4uC, after which it was deep frozen to 280uC until sampling.
Metabolite Measurements
Metabolomic analysis was performed on 3061 subjects from the
population-based cohort KORA F4 and on 377 subjects of the
population-based cohort KORA F3. Men and women were
collected in a random order and samples were randomly put on
plates to exclude batch effects.
Liquid handling of serum samples (10 ml) was performed with
Hamilton Star (Hamilton Bonaduz AG, Bonaduz, Switzerland)
robot and prepared for quantification using the AbsoluteIDQ kit
(BIOCRATES Life Sciences AG, Innsbruck, Austria) as described
previously [1]. Sample analysis were done on API 4000 QTrap
LC/MS/MS System (Applied Biosystems, Darmstadt, Germany)
equipped with Schimadzu Prominence LC20AD pump and SIL-
20AC auto sampler. The complete analytical process was
monitored with the MetIQTM software package, which is an
integral part of the AbsoluteIDQTM kit.
Metabolite Panel
In total, 163 different metabolites were quantified. More
information about the metabolite panel can be found in Text
S1. Metabolite measurements of the 3061 samples were performed
in three batches, with two and three months time lapse in between,
respectively. Within each kit, there are three different quality
controls (QCs) representing gender mixed human plasma samples
provided by the manufacturer. In accordance with the kit
instructions, concentration of each metabolite was adjusted based
on the three QCs to minimize the potential batch effects.
To ensure data quality, metabolites had to meet three criteria:
(1) average value of coefficient of variance (CV) of the three QCs
should be smaller than 25%. (2) 90% of all measured sample
concentrations should be above the limit of detection (LOD). (3)
Correlation coefficients between two duplicated measurements of
144 re-measured samples should be above 0.5 (Table S6). In total,
131 metabolites passed the three quality controls. To detect
sample outliers, the data of the 131 metabolite concentrations
were first scaled to zero mean and unity standard deviation and
were projected onto the unit sphere and Mahalanobis distances
were then obtained. Robust principal components algorithm was
used in the process [29]. Mean and variance were then calculated
for the distances. A cut-off was set at 3 times variance plus mean
distance. Any individual, whose distance was greater than this cut-
off, was marked as an outlier and removed. Outliers were detected
separately for males and females. 131 Metabolites and 3004
samples remained in the dataset. Missing values were using the R
package ‘‘mice’’. Metabolite concentrations were logarithmized for
all subsequent analysis steps.
Genotyping and Imputation
In KORA F4 genome-wide genotyping was done using the
Affymetrix 6.0 GeneChip array (Geno-KORA F4). The algorithm
Birdseed2 was used for calling. Genotyped SNPs were filtered for
an individual call rate of 0.93, SNP call rate 0.93 and Hardy-
Weinberg equilibrium (PHWE .0.001). All remaining SNPs
(651,596) were used for imputation with MACH (v1.0.15).
HapMap CEU version 22 was used as reference population for
calling and imputation. The GWAS replication cohort Rep-
KORA F4 was genotyped on Metabo-Chip, with calling algorithm
GenomeStudio. The second GWAS replication sample KORA F3
was genotyped with the Affymetrix 500 K array. The calling was
performed by BRLMM with reference population HapMap CEU
21. After filtering for individual call rate 0.93 and SNP call rate 0.9
and Hardy-Weinberg equilibrium (PHWE .0.001) the remaining
SNPs were imputed with MACH v1.0.9 using HapMap CEU
version 21 as reference population.
Statistical Analysis
Partial least squares (PLS). PLS, or projection to latent
structures by means of partial least squares, and is a method to
relate a matrix X to a vector y (or to a matrix Y).The x-data are
transformed into a set of a few intermediate linear latent variables
(components). PLS analysis [10] was carried out using the R
package pls to investigate the metabolic profiles of males and
females. Data was visualized by plotting the scores of the first two
components against each other, where each point represented an
individual serum sample. For this analysis, metabolite
concentrations were normalized to have a mean of zero and a
standard deviation of one.
Delta (difference in concentration means for men and
women). For comparison of metabolite concentrations between
men and women we used the delta (D), as it describes the
difference in concentration means for men and women for a
specific metabolite relative to the mean metabolite concentration
in men. Therefore the difference of mean metabolite
concentration in men and mean metabolite concentration in
women is calculated and than divided by the mean metabolite
concentration in men. For example, a value of D=50% means,
that the mean metabolite concentration in women is 50% lower
than the metabolite concentration in men.
Linear regression. Metabolite concentration differences
between males and females were investigated by linear regression
analysis. The basic model contains the log-transformed metabolite
as dependent, sex as explanatory variable and both age and BMI as
covariates. Moreover, an internal batch variable is included to
account for possible systematic differences that might have been
caused by the metabolite measuring process. To correct for multiple
testing Bonferroni-correction was applied. That means the influence
of sex on a specific metabolite was called significant, if the p-value of
the corresponding test of sex having no effect on (log-transformed)
metabolite is lower than 0.05/131=3.861024. For replication we
also applied Bonferroni-correction. That means a difference in sex
on a specific metabolite is called significant, if the direction of the
effect in consistent between discovery and replication cohort and the
p-value for sex having no effect on the metabolite is lower than 0.05
corrected for the number of metabolites taken forward for
replication.
We analysed the influence of anthropometric phenotypes,
diseases and environmental factors by including different covar-
iates to the linear regression and comparison of the structure of the
results. Four models which differ in the use of one or more
additional covariates were performed. The covariates in each
model beside age are waist hip ratio (WHR), lipid parameters
(HDL and LDL cholesterol, triglycerides), type 2 diabetes, alcohol
consumption and smoking. All calculations were performed in R
with standard procedures (lm). Furthermore, a meta-analysis of the
discovery and the replication sample with a fixed effect model was
analyzed to reveal the sex-specific effects of metabolite concen-
trations.
Partial correlation analysis. In order to investigate how
strong the different metabolites correlate with each other and the
Sex-Specific Metabotypes in Human Metabolism
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sex-specific effects propagate through the underlying metabolic
network, we calculated full-order partial correlation coefficients (r)
between all pairs of metabolites. The resulting partial correlation
networks are commonly referred to as Gaussian graphical models
(GGMs), which we have previously demonstrated to be useful for
the analysis of direct metabolite-metabolite effects in the same
population cohort [11]. The GGM was coloured and annotated
according to the b-values and p-values from linear regression
analysis and then exported and visualized using the free yEd graph
editor.
Genome-wide association studies (GWAS). We calculated
GWAS for all 131 metabolites with mach2qtl (v1.0.8) for men and
women separately. We applied an additive model with covariates
age, BMI and an internal variable accounting for batch effects.
Genome-wide test for sex-specific differences in beta-
estimates. We tested each SNP and metabolite for equality of
the beta-estimates for the SNP calculated in the sex-specific
GWAS. Therefore we used an approximately normally distributed
test statistic [30]:
bmen{bwomenffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
se(bmen)
2zse(bwomen)
2
q
To take our 131 phenotypes into account we used Bonferroni
correction. Therefore the genome-wide significance level is
561028/131= 3.8610210 [31].
Replication of sex-specific differences in genetic
effects. We confirm a genetic sex-specific difference as
replicated, if the proportion of the absolute SNP effects in men
and women is the same as in the discovery sample, and the p-value
for the test for difference in effects is lower than the adjusted p-
value.
Replication in KORA F4. We used PLINK for the
calculation.
Further analysis. All further analyses were performed in R.
For both subgroups, men and women, we calculated the
frequencies of each SNP. The explained variance (R2) for each
SNP and metabolite was calculated as the difference of the
coefficients of determination of the model with SNP and without
SNP. The metaanalysis of SNP association with glycine was
performed with METAL (http://www.sph.umich.edu/csg/
abecasis/Metal/index.html) for men and women separately
using the inverse variance weighting.
Supporting Information
Figure S1 KORA study populations with subsamples used in
this study.
(TIFF)
Figure S2 QQ-plots for the sex-stratified GWAS with glycine.
The QQ-plot shows the p-values of the sex stratified GWAS for
glycine in the discovery sample Geno-KORA F4 versus the
expected p-values under the null hypotheses of no SNP having an
effect on glycine.
(JPG)
Figure S3 Regional association plots for sex-stratified GWAS
with glycine around the locus CPS1. Association p-values of SNPs
with glycine for men and women are presented for a region
surrounding rs715, which had the strongest difference in beta-
estimates between men and women. SNPs with genome-wide
significant differences in beta-estimates are highlighted in blue.
The level of linkage disequilibrium of rs715 with other SNPs is
indicated by circle colour ranging from red r2.0.8, orange
0.8.r2.0.5, grey 0.5.r2.0.2 to white 0.2.r2.
(TIFF)
Figure S4 Distribution of partial correlation coefficients. Partial
correlations center around zero with a shift towards positive high
values. When applying a correlation cutoff of r = 0.3, we are left
with 109 out of 8515 correlation values (1.28%).
(TIFF)
Figure S5 Number of clustered groups in the GGM as a
function of the absolute partial correlation cutoff. Note that we did
not count singleton metabolites that is metabolites without any
partial correlation above threshold, here. Most non-singleton
groups emerge in the cutoff range between 0.3 and 0.7, which
corresponds to the figure in the main manuscript. For our lower
cutoff of 0.3, we obtain 14 groups, which can here be regarded as
independent phenotypes in the metabolite pool.
(TIFF)
Table S1 Study population characteristics. Data are presented
as mean (SD) or number of persons (N); BMI indicates body mass
index; HDL high density lipoprotein; LDL low density lipoprotein;
smokers: number of smokers with one or more than one cigarette/
day, high alcohol intake: subjects were counted for high alcohol
intake when they had an alcohol consumption of $0 g alcohol/
day for males and $20 g alcohol/day for females. (A) Study
populations used for phenotypic analysis. (B) Study populations
used for genotypic analysis.
(DOCX)
Table S2 Phenotypic metabotype differences between males and
females of the discovery sample KORA F4. P-values were
calculated by a linear regression model with metabolite concen-
tration as outcome and sex as explanatory variable adjusted for
different covariables. Gray shaded columns show significant p-
values for differences in the metabolite concentrations between
males and females after Bonferroni correction (significance level
after multiple testing correction = p-value,3.861024).
(DOCX)
Table S3 Phenotypic metabotype differences between males and
females of the replication sample KORA F3. P-values were
calculated by a linear regression model with metabolite concen-
tration as outcome and sex as explanatory variable adjusted for
age, BMI and waist-hip ratio (WHR). Gray shaded columns show
significant p-values for differences in the metabolite concentrations
between males and females after Bonferroni correction (signifi-
cance level after multiple testing = p-value,3.861024).
(DOCX)
Table S4 Comparison of different adjustments in association of
SNPs with glycine. Results for SNPs which showed a significant
difference in beta-estimates for KORA F4 with the adjustment of
sex-specific GWAs for BMI (age, batch), for different adjustment
for waist-hip ratio (WHR) (age, batch) or adjustment for WHR
and BMI (age, batch).
(DOCX)
Table S5 Detailed information for SNPs with significant gender
differences in beta-estimates for association with glycine. Minor
allele frequency is calculated for men and women separately in
each study. Imputation quality (RSQ) respectively call rate for
genotyped SNPs is calculated based on all IDs.
(DOCX)
Table S6 Full biochemical names of all 131 metabolites used for
further analysis that were measured on the Biocrates Absolute
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IDQ kit. Abbreviations and full biochemical names of the 131
metabolites are shown in the first and second columns,
respectively. The third column lists shows the correlation
coefficients (r) between two duplicated measurements of 144 re-
measured samples. The following column shows percentage of
3061 individuals above limit of detection (LOD) and the last
column shows the mean value of the correlation coefficient (CV) of
the three quality controls for the three batches.
(DOCX)
Table S7 Excluded metabolites that were measured on the
Biocrates AbsoluteIDQ kit. Abbreviations and full biochemical
names of the excluded metabolites are shown in the first and
second columns, respectively. The third column shows the
correlation coefficients (r) between two duplicated measurements
of 144 re-measured samples. The following column shows
percentage of 3061 individuals above limit of detection (LOD).
Mean value of the correlation coefficient (CV) of the three quality
controls for the three batches is shown in the last column.
(DOCX)
Table S8 Metabolite concentrations of the study cohorts KORA
F4 and KORA F3 and the relative sex-specific difference (D in %).
D= (Mean(metabolite concentration of men) – mean(metabolite
concentration of women) ) /mean (metabolite concentration of
men); difference of metabolite concentrations between men and
women in %.
(DOCX)
Text S1 Metabolite panel.
(DOC)
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